In colon cancer cells blockade of EGFR by the antibody cetuximab or by EGFR small molecule inhibitors such as gefitinib or erlotinib proves strongly synergistic with BRAFV600E inhibition in suppressing MAPK signaling and reducing cell viability [13]. Here, EGFR is linked to malignant colon neoplasm.